CTIS2024-516718-39-00进行中（未招募）1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years, Advanced or metastatic melanoma or RCC, Current treatment with nivolumab in a 6 mg/kg or 480 mg, 4 weekly scheme, Documented confirmed and ongoing CR, PR or SD according to RECIST v1.1, On treatment for at least 6 months
排除标准
- •Unable to draw blood for study purposes, Patients willing to participate or already included in the SAFE-STOP trial
研究者
相似试验
进行中（未招募）
1 期
ivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)Patients with advanced or metastatic melanoma or renal cell carcinoma treated with nivolumab monotherapy in a 480mg or 6 mg/kg 4 weekly scheme (either from start or after combination therapy with ipilimumab), have a confirmed CR, PR or SD, are at least 6 months on treatment and are willing to receive 3 reduced doses of 240 mgEUCTR2021-001707-32-NLErasmus Medical Center Rotterdam91
招募中
不适用
ivolumab dose optimization during nivolumab therapy in melanoma patients after achieving a complete, partial or stable response (NIVOPTIMIZE-trial)10040900melanomaskin cancerNL-OMON54156Erasmus MC, Universitair Medisch Centrum Rotterdam34
已完成
2 期
ivolumab monotherapy in Rare tumor patients with mismatch repair deficiency biomarker: A phase II trialRare cancers with MSI-high or dMMRJPRN-jRCT2091220344Kan Yonemori, National Cancer Center Hospital15
进行中（未招募）
1 期
Golimumab dose variation to achieve response in Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2015-004724-62-IECD136
进行中（未招募）
1 期
An investigational immunotherapy study of Nivolumab combined with chemoradiotherapy , compared to chemoradiotherapy by itself, in patients with bladder cancer, not undergoing cystectomymuscle-invasive bladder cancer (MIBC)MedDRA version: 20.0 Level: PT Classification code 10005003 Term: Bladder cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003447-34-GRHellenic Genitourinary Cancer Group (HGUCG)78